New performance of biosensor technology for Alzheimer's disease drugs: in vitro comparison of tacrine and 7-methoxytacrine
Language English Country Sweden Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
18987590
PII: NEL290508A24
Knihovny.cz E-resources
- MeSH
- Acetylcholinesterase chemistry MeSH
- Algorithms MeSH
- Alzheimer Disease drug therapy MeSH
- Biosensing Techniques * MeSH
- Cholinesterase Inhibitors analysis MeSH
- Electrochemistry MeSH
- Enzymes, Immobilized chemistry MeSH
- Kinetics MeSH
- Humans MeSH
- Nootropic Agents analysis MeSH
- Tacrine analogs & derivatives analysis MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- 7-methoxytacrine MeSH Browser
- Acetylcholinesterase MeSH
- Cholinesterase Inhibitors MeSH
- Enzymes, Immobilized MeSH
- Nootropic Agents MeSH
- Tacrine MeSH
Two drugs were tested using electrochemical biosensor with immobilized acetylcholinesterase (AChE). The first was commercialized drug tacrine (known also as Cognex) used for treatment of cognitive manifestation of Alzheimer\'s disease (AD). The second one was its 7-methoxy derivate (7-MEOTA) that has not been marketed. We determined the IC50 (6.67+/-0.92)x10-7 M for tacrine and (1.66+/-1.43)x10-9 M for 7-MEOTA. In this in vitro study, 7-MEOTA acts as stronger inhibitor of AChE and in this way could be more favorable for treatment of cognitive manifestation of AD. Our study shows that biosensor technology could be used as a quick and cheap tool for testing of promising AChE inhibitors (AD drug candidates).
Cholinesterase based amperometric biosensors for assay of anticholinergic compounds
